Showing results (91-100 of 105) with videos related to
Sort By:
Pageof 11
Nature Metabolism|June 14, 2024
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancerHyun Min Lee, Nefertiti Muhammad, Elizabeth L Lieu, et al.The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.Bioorganic & Medicinal Chemistry Letters|December 3, 2014
A reversed sulfonamide series of selective RORc inverse agonistsMonique B van Niel, Benjamin P Fauber, Matthew Cartwright, et al.Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.Journal of Pharmaceutical Sciences|October 5, 2007
N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerationsKan He, Mingxin Qian, Harvey Wong, et al.Journal of Medicinal Chemistry|June 26, 2009
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Maria Rafalski, et al.Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.JCI Insight|April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.Pageof 11